Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

P4-12-12: Patient-, Illness-, and/or Treatment-Related Baseline Predictors of Nonadherence to Oral Hormonal Therapy.

View through CrossRef
Abstract Background: Nonadherence to oral hormonal therapy is problematic for women with breast cancer. Patient-, illness-, and treatment-related factors have been associated with nonadherence, but with inconsistent findings. Therefore, our aim was to explore predictors of nonadherence to hormonal therapy for women with early stage breast cancer from the baseline assessment (pre-hormonal therapy) to 6 months post-treatment. Methods: A secondary analysis was performed to explore potential patient-, illness-, and treatment-related predictors of nonadherence for 198 women enrolled in either: 1) The Anastrozole Use in Menopausal Women Study (AIM Study, n=162), or, 2) Predictors of Adherence to Hormonal Therapy in Breast Cancer (ONS Study, n=36). Nonadherence was defined as the percentage of prescribed administrations of hormonal therapy that were not taken during the first 6 months of therapy as measured using an electronic Drug Exposure Monitor (eDEM) (AARDEX, Ltd.). Chi-square tests of independence and Mann-Whitney U tests were performed to determine whether data from the two studies could be pooled. Descriptive statistics were performed to characterize the sample. Multiple linear regression analyses were performed to identify the best model in two stages: 1) univariate relationships between each candidate predictor variable and the outcome variable (6-month nonadherence) were assessed using a cut-off of p=.20; and, 2) candidate predictors meeting the criteria were retained for further exploration in model-building multiple linear regression analyses (stepwise and backward) to determine the predictors of 6-month nonadherence summary scores. Candidate predictors were retained in the model if they remained associated at p<.10 in the multiple linear regression analysis. Results: Women were 98.3% Caucasian with a mean age 59.1 years (SD 7.5) and mean number of years of education of 15.0 (SD 2.9). Overall mean nonadherence was 11.6% (13.2% AIM Study, 4.6% ONS Study). Chi-square and Mann-Whitney U tests demonstrated that the two samples could be pooled, given the data were similar on key variables (number of years of education, depression, anxiety, fatigue, symptoms, and nonadherence). Both stepwise and backward elimination modeling algorithms demonstrated evidence of 3 significantly significant variables associated with nonadherence; however, the backward elimination model best represented the sample (R2=.106, adjusted R2=.086, s=0.28490). Women who worked (p=.082), whose primary occupation was clerical or administrative (p=.029), had DCIS tumor type (p=.017), or who had higher gastrointestinal (GI) symptoms scores (p=.013) were associated with nonadherence. The potential for interactions between primary occupation, DCIS tumor type, and higher GI symptoms was explored and was not significant. In addition, while all tumor types were examined as candidate predictors, participants with DCIS also had another tumor to be eligible for the parent studies. Conclusions: Our study offers insight into potential predictors of nonadherence for women participating in one of two cohort studies. The findings suggest additional examinations of nonadherence concerning work and symptom burden and their relationship to nonadherence are indicated. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-12-12.
American Association for Cancer Research (AACR)
Title: P4-12-12: Patient-, Illness-, and/or Treatment-Related Baseline Predictors of Nonadherence to Oral Hormonal Therapy.
Description:
Abstract Background: Nonadherence to oral hormonal therapy is problematic for women with breast cancer.
Patient-, illness-, and treatment-related factors have been associated with nonadherence, but with inconsistent findings.
Therefore, our aim was to explore predictors of nonadherence to hormonal therapy for women with early stage breast cancer from the baseline assessment (pre-hormonal therapy) to 6 months post-treatment.
Methods: A secondary analysis was performed to explore potential patient-, illness-, and treatment-related predictors of nonadherence for 198 women enrolled in either: 1) The Anastrozole Use in Menopausal Women Study (AIM Study, n=162), or, 2) Predictors of Adherence to Hormonal Therapy in Breast Cancer (ONS Study, n=36).
Nonadherence was defined as the percentage of prescribed administrations of hormonal therapy that were not taken during the first 6 months of therapy as measured using an electronic Drug Exposure Monitor (eDEM) (AARDEX, Ltd.
).
Chi-square tests of independence and Mann-Whitney U tests were performed to determine whether data from the two studies could be pooled.
Descriptive statistics were performed to characterize the sample.
Multiple linear regression analyses were performed to identify the best model in two stages: 1) univariate relationships between each candidate predictor variable and the outcome variable (6-month nonadherence) were assessed using a cut-off of p=.
20; and, 2) candidate predictors meeting the criteria were retained for further exploration in model-building multiple linear regression analyses (stepwise and backward) to determine the predictors of 6-month nonadherence summary scores.
Candidate predictors were retained in the model if they remained associated at p<.
10 in the multiple linear regression analysis.
Results: Women were 98.
3% Caucasian with a mean age 59.
1 years (SD 7.
5) and mean number of years of education of 15.
0 (SD 2.
9).
Overall mean nonadherence was 11.
6% (13.
2% AIM Study, 4.
6% ONS Study).
Chi-square and Mann-Whitney U tests demonstrated that the two samples could be pooled, given the data were similar on key variables (number of years of education, depression, anxiety, fatigue, symptoms, and nonadherence).
Both stepwise and backward elimination modeling algorithms demonstrated evidence of 3 significantly significant variables associated with nonadherence; however, the backward elimination model best represented the sample (R2=.
106, adjusted R2=.
086, s=0.
28490).
Women who worked (p=.
082), whose primary occupation was clerical or administrative (p=.
029), had DCIS tumor type (p=.
017), or who had higher gastrointestinal (GI) symptoms scores (p=.
013) were associated with nonadherence.
The potential for interactions between primary occupation, DCIS tumor type, and higher GI symptoms was explored and was not significant.
In addition, while all tumor types were examined as candidate predictors, participants with DCIS also had another tumor to be eligible for the parent studies.
Conclusions: Our study offers insight into potential predictors of nonadherence for women participating in one of two cohort studies.
The findings suggest additional examinations of nonadherence concerning work and symptom burden and their relationship to nonadherence are indicated.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-12-12.

Related Results

Blogging Illness: Recovering in Public
Blogging Illness: Recovering in Public
As a mode of open access public self-expression, blogs are one form of the unfolding massification of culture (Lovink). Though widely varied in content and style, they are characte...
Autonomy on Trial
Autonomy on Trial
Photo by CHUTTERSNAP on Unsplash Abstract This paper critically examines how US bioethics and health law conceptualize patient autonomy, contrasting the rights-based, individualist...
642-P: Discovering Nonadherence to Diabetes Medications—Which Questions Are Most Effective?
642-P: Discovering Nonadherence to Diabetes Medications—Which Questions Are Most Effective?
Half of patients with diabetes have difficulty taking medications as directed, creating a major barrier to glycemic control. In studies outside of diabetes, specific, negatively-fr...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Immunosuppressant nonadherence profile in kidney transplant recipients and the impact of medication adherence on transplant outcomes
Immunosuppressant nonadherence profile in kidney transplant recipients and the impact of medication adherence on transplant outcomes
BackgroundDespite the fact that 1-year graft and recipient survival rates are above 90% in most transplant centers, improving long-term graft survival remains an important challeng...
Nonadherence in diabetes care among US adults with diabetes by stroke status
Nonadherence in diabetes care among US adults with diabetes by stroke status
Objective Effects of stroke (i.e., memory loss, paralysis) may make effective diabetes care difficult which can in turn contribute to additional diabetes related complications and ...
Pembrolizumab and Sarcoma: A meta-analysis
Pembrolizumab and Sarcoma: A meta-analysis
Abstract Introduction: Pembrolizumab is a monoclonal antibody that promotes antitumor immunity. This study presents a systematic review and meta-analysis of the efficacy and safety...
The Impact of IL28B Gene Polymorphisms on Drug Responses
The Impact of IL28B Gene Polymorphisms on Drug Responses
To achieve high therapeutic efficacy in the patient, information on pharmacokinetics, pharmacodynamics, and pharmacogenetics is required. With the development of science and techno...

Back to Top